Antiretroviral agents in the pipeline;ANTIRETROVIRALE GENEESMIDDELEN IN DE PIJPLIJN

Pharmaceutisch Weekblad

Volumn 133, Issue 6, 1998, Pages 273-279

  Burger, D M ^a   Hoetelmans, R M W ^b   Koopmans, P P ^a   Hekster, Y A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOVIRIDE; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE;

ARTICLE; DRUG MECHANISM; DRUG RESEARCH; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; VIREMIA; VIRUS REPLICATION;

EID: 0032488782     PISSN: 00316911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (6)

1. 11th International Conference on AIDS; 1996 Jul 7-12; Vancouver.
2. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1996 sep 15-18; New Orleans.
3. 3rd International Congress on Drug Therapy in HIV Infection; 1996 nov 3-7; Birmingham.
4. 4th Conference on Retroviruses and Opportunistic Infections; 1997 jan 22-26; Washington. Belangstellenden kunnen kopieën aanvragen bij de auteur
5. Freimuth W. Delavirdine mesylate, a potent non-nucleoside HIV-1 reverse transcriptase inhibitor Adv Exp Med Biol 1996;394:279-89.
6. Murphy RL, Montaner J. Nevirapine: a review of its development, pharmacological profile and potential for clinical use. Exp Opin Invest Drugs 1996,5(9);1183-99.